$EVO earnings report

NINE-MONTH 2026 RESULTS ABOVE MARKET EXPECTATIONS; FULL-YEAR 2026 GUIDANCE REAFFIRMED. AlphAI read Evotec's 9M 2026 filing as mixed. 2 quarters are on record below.

9M 2026

AlphAI · Earnings readEVO · 9M 2026 · ended September 30, 2026

NINE-MONTH 2026 RESULTS ABOVE MARKET EXPECTATIONS; FULL-YEAR 2026 GUIDANCE REAFFIRMED

→Mixed quarter

Revenue, gross margin, adjusted Group EBITDA, net loss and operating cash flow deteriorated year over year, while Evotec reaffirmed its full-year 2026 revenue and adjusted Group EBITDA guidance and reported Horizon slightly ahead of schedule.

Revenue
€465M
decreased by 13.1% y/y
Discovery & Preclinical Development (D&PD), 9M 2026
€348M
declined by 11.2% y/y
Gross margin · other
3.6%
EPS · other
(1.10)
Full-year 2026 outlook
€ 570 – 610 m (€ 595 – 635 m CER; 2025: € 788.4 m)

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Group revenue, 9M 2026other€465M–decreased by 13.1%
Group revenue at constant exchange rates, 9M 2026other€477.4M–declined by 10.8%
Base revenue, 9M 2026other€441.1M–decreased by 12.4%
Cost of revenue, 9M 2026other€448.4M––
Gross profit, 9M 2026other€16.65M––
Group gross margin, 9M 2026other3.6%––
Research and development costs, 9M 2026other€29.7M–decreased by 29.8%
Selling, general and administrative expenses, 9M 2026other€121.9M–€ 16.5 m or 11.9% lower
Other operating income, 9M 2026other€31.2M––
Other operating expenses, 9M 2026other€59.1M––
Reorganization costs, 9M 2026other€91.9M––
Operating loss, 9M 2026other€254.8M––
Adjusted Group EBITDA, 9M 2026non-GAAP−€44.3M––
Net loss, 9M 2026other€195.3M––
Net result per share, basic, 9M 2026other(1.10)––
Net result per share, diluted, 9M 2026other(1.10)––
Average employees, 9M 2026other4,379 people–decrease of 378 (7.9%)

Segments

SegmentRevenueq/qy/y
Discovery & Preclinical Development (D&PD), 9M 2026The decrease was primarily driven by lower sales-to-revenue conversion across all D&PD business areas, reflecting ongoing timing effects in commercial activities despite early signs of improvement in the market.€348.2M–declined by 11.2%
Just – Evotec Biologics (JEB), 9M 2026The decline was primarily driven by the USD 25 m Sandoz license sale recognized in Q1 2025 and delayed program activities.€117.1M–decreased by 18.3%

Full-year 2026 outlook

  • Revenue€ 570 – 610 m (€ 595 – 635 m CER; 2025: € 788.4 m)
  • NoteAdjusted Group EBITDA is expected to reach € (70) – (105) m (€ (60) – (90) m CER; 2025: € 41.1 m).

What drove it

  • D&PD revenue was affected by lower sales-to-revenue conversion across all business areas and timing effects in commercial activities.
  • JEB revenue was affected by the USD 25 m Sandoz license sale recognized in Q1 2025, delayed program activities and customer project progression.
  • D&PD gross margin was affected by lower top-line performance and continued underutilization.
  • JEB gross margin reflected delayed program activities, temporarily higher material and project costs due to production phasing, and the Sandoz license income in Q1 2025.
  • R&D expenses declined through more focused capital allocation to selected R&D projects.
  • D&PD SG&A declined mainly due to lower personnel costs following Horizon and reduced consultancy expenses.
  • Horizon is progressing slightly ahead of schedule and supports the plan to realize 20–30% of the € 75 m run-rate savings from 2027 into 2026.

Concerns

  • Group gross margin fell to 3.6% from 10.7%, including a JEB gross margin of (9.5)% compared with 2.7%.
  • Adjusted Group EBITDA loss widened to € (44.3) m from € (16.9) m.
  • Reorganization costs were € 91.9 m, including € 43.3 m attributable to personnel measures and € 43.1 m of impairment losses on property, plant and equipment at affected sites.
  • Other operating expenses included an impairment loss of € 42.3 m relating to a laboratory building in Hamburg.
  • Net cash used in operating activities was € (155.0) m, compared with € (72.8) m.
  • Total Liquidity decreased to € 400.9 m from € 476.4 m, while Current and Non-current financial liabilities increased to € 481.8 m from € 448.7 m.

What to watch

  • Sales-to-revenue conversion and timing effects across D&PD business areas.
  • JEB customer project progression, program-related activities, production phasing and material costs.
  • Delivery of Horizon measures and realization of 20–30% of the € 75 m run-rate savings from 2027 into 2026.
  • The full-year 2026 revenue range of € 570 – 610 m and adjusted Group EBITDA range of € (70) – (105) m.
  • Operating cash flow, liquidity and financial liabilities following nine-month operating cash use of € (155.0) m.

Balance sheet and cash flow

  • Net cash provided by (used in) operating activities, 9M 2026: € (155.0) m (9M 2025: € (72.8) m).
  • Net cash provided by (used in) investing activities, 9M 2026: € 14.8 m (9M 2025: € (50.8) m).
  • Capital expenditure, 9M 2026: € (19.2) m (9M 2025: € (57.8) m).
  • Proceeds from the disposal of Tubulis GmbH, net of hedging: € 87.8 m.
  • Net cash provided by (used in) financing activities, 9M 2026: € 23.0 m (9M 2025: € 8.6 m).
  • Cash and cash equivalents as of September 30, 2026: € 299,012 k (December 31, 2025: € 418,517 k).
  • Total Liquidity (Cash and cash equivalents and Current investments): € 400.9 m (December 31, 2025: € 476.4 m).
  • Current and Non-current financial liabilities: € 481.8 m (December 31, 2025: € 448.7 m).
  • Total assets: € 1,505.0 m (December 31, 2025: € 1,713.9 m).
  • Total liabilities: € 863.3 m (December 31, 2025: € 900.2 m).
  • Total stockholders’ equity: € 641.7 m (December 31, 2025: € 813.7 m).
  • Equity ratio as of September 30, 2026: 42.6% (December 31, 2025: 47.5%).

Analysis

Evotec reported nine-month revenue of € 465.0 m, down 13.1% from € 535.1 m, with base revenue decreasing 12.4% to € 441.1 m. At constant exchange rates, Group revenue declined 10.8% to € 477.4 m. D&PD revenue declined 11.2% to € 348.2 m as lower sales-to-revenue conversion and commercial timing effects affected all business areas. JEB revenue decreased 18.3% to € 117.1 m, reflecting the USD 25 m Sandoz license sale recognized in Q1 2025 and delayed program activities.

Profitability weakened materially. Group gross margin fell to 3.6% from 10.7%, with D&PD margin decreasing to 8.0% from 13.6% and JEB margin falling to (9.5)% from 2.7%. Lower revenue and underutilization pressured D&PD, while JEB absorbed delayed program activity and temporarily higher material and project costs from production phasing. Adjusted Group EBITDA was a loss of € (44.3) m, compared with a loss of € (16.9) m, despite lower R&D and SG&A expenses.

The reported net loss widened to € 195.3 m from € 118.1 m. The period included € 91.9 m of Horizon-related reorganization costs and an impairment loss of € 42.3 m relating to a Hamburg laboratory building. Horizon-related costs included € 43.3 m for personnel measures and € 43.1 m of property, plant and equipment impairment losses at affected sites. Management stated that Horizon is progressing slightly ahead of schedule and remains positioned to bring 20–30% of the € 75 m run-rate savings planned for 2027 into 2026.

Cash generation and liquidity remain key points of attention. Operating cash flow was € (155.0) m, versus € (72.8) m in 9M 2025. Investing cash flow was positive at € 14.8 m, supported by proceeds from the Tubulis GmbH disposal, while financing cash flow was € 23.0 m, driven by convertible bonds and other loans partly offset by debt and lease repayments. Total Liquidity declined to € 400.9 m and Current and Non-current financial liabilities increased to € 481.8 m.

Evotec reaffirmed full-year 2026 guidance for Group revenues of € 570 – 610 m and adjusted Group EBITDA of € (70) – (105) m. The filing characterizes nine-month revenue and adjusted EBITDA as consistent with the full-year guidance ranges. The principal execution markers for the remainder of the year are D&PD sales conversion, JEB program timing and project progression, realization of Horizon savings, and the trajectory of operating cash use.

Not in the filing

stated, not guessed
  • Standalone Q3 2026 financial statements and standalone Q3 2025 comparisons were not provided.
  • Prior-quarter comparisons for reported nine-month metrics were not provided.
  • Free cash flow was not reported.
  • Dividend payments, share repurchases and other capital-return programs were not reported.
  • A separate debt figure was not reported; the filing reports Current and Non-current financial liabilities.
  • Forward guidance for gross margin, operating expenses and tax rate was not provided.
  • Named executive earnings commentary and attributable executive quotes were not provided.
  • The accounting framework was not specified in the provided filing text.
  • The previous outlook covered the full year 2026, and this release reports the nine months to September 30, 2026, so there is no matching guidance to compare.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

6M 2026

AlphAI · Earnings readEVO · 6M 2026 · ended June 30, 2026

Group revenues decreased by 19.2% to € 300.1 m and Adjusted Group EBITDA totaled € (42.7) m; FY 2026 outlook was updated for partnership timing shifts and lower revenue conversion.

↓Weak quarter

Revenue declined across both segments, gross margin turned negative, adjusted EBITDA loss widened, net loss increased, and FY 2026 revenue and adjusted EBITDA guidance was reduced.

Revenue
€300M
(19.2)% y/y
Discovery & Preclinical Development (D&PD)
€228M
(15.2)% y/y
Gross margin · other
(1.0)%
EPS · other
(0.95)
FY 2026 outlook
€ 570 – 610 m (€ 595 - 635 m CER; 2025: € 788.4 m)

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Group revenueother€300.1M–(19.2)%
Group revenue at constant exchange ratesother€313.2M–(15.6)%
Base revenuesother€285.8M–(17.8)%
Cost of revenueother−€303.3M––
Gross profit (loss)other−€3.15M––
Gross marginother(1.0)%––
Research and development costsother−€20.34M–(30.8)%
Selling, general and administrative expensesother−€83.08M–(11.1)%
Other operating incomeother€22.03M––
Other operating expensesother−€51.21M––
Reorganization costsother−€98.92M––
Operating income (loss)other−€234.7M––
Adjusted Group EBITDAnon-GAAP−€42.68M––
Realized gain (loss) on investments and financial instruments revaluationother€70.03M––
Net income (loss) before taxesother−€170.3M––
Income taxesother€1.72M––
Net income (loss)other−€168.6M––
Net result per share (basic)other(0.95)––
Net result per share (diluted)other(0.95)––
Net cash provided by (used in) operating activitiesother−€111.1M––
Capital expenditureother−€13.3M––
Net cash provided by (used in) investing activitiesother€7.08M––
Net cash provided by (used in) financing activitiesother€33.77M––
Cash and cash equivalentsother€348.4M––
Total Liquidityother€465.6M––
Current and Non-current financial liabilitiesother€475.9M––
Total stockholders' equityother€665.6M––
Equity ratioother42.3%––

Segments

SegmentRevenueq/qy/y
Discovery & Preclinical Development (D&PD)The decline was primarily driven by weak sales conversion across all business areas and softer-than-expected customer demand, reflecting the continued challenging market environment.€227.9M–(15.2)%
Just – Evotec Biologics (JEB)The decline was primarily driven by the Sandoz License sale in Q1 2025. Excluding Sandoz License sale and negative FX-impact, revenues decreased by 2.3%.€72.25M–(29.3)%

FY 2026 outlook

  • Revenue€ 570 – 610 m (€ 595 - 635 m CER; 2025: € 788.4 m)
  • NoteAdjusted Group EBITDA is expected to reach € (70) – (105) m (€ (60) - (90) m CER; 2025: € 41.1 m)

Capital returns

  • Evotec successfully placed € 116.1 m convertible bonds.
  • Proceeds from convertible bonds and other loans were € 112,931k.
  • Repayment of loans was € (65,791)k.
  • Repayment of lease liabilities was € (10,482)k.

What drove it

  • D&PD net sales excluding strategic partnerships increased by 28% YoY, reflecting strong customer engagement and commercial execution.
  • JEB showed continued progress with high capacity utilization and an expanded customer base.
  • R&D expenses decreased to € 20.3 m, driven by more focused capital allocation to selected R&D projects.
  • SG&A expenses decreased by € 10.3 m or 11.1%, mainly driven by lower IT business consultancy expenses in D&PD.
  • Project Horizon structural measures are expected to generate ~ € 75 m run-rate savings by end of 2027.
  • The sale of Tubulis GmbH generated a gain on disposal of € 71,929k.

Concerns

  • Customers continue to act cautiously amid ongoing economic, regulatory and geopolitical uncertainties, and any broader recovery in demand is expected to occur gradually.
  • D&PD continued to experience underutilization.
  • Group gross margin declined to (1.0)% from 13.6%.
  • JEB gross margin declined to (18.3)% from 9.1%, reflecting delayed program activities, temporarily higher material and project costs due to production phasing, and the Sandoz License sale in Q1 2025.
  • Other operating expenses included a € 42.3 m impairment loss relating to a laboratory building in Hamburg.
  • Reorganization costs amounted to € 98.9 m for Project Horizon.

What to watch

  • Revenue conversion and customer demand across D&PD business areas.
  • D&PD utilization and the execution of Project Horizon operational and cost initiatives.
  • JEB program activity timing, material and project costs, capacity utilization, and customer-base expansion.
  • Delivery against FY 2026 Group revenue guidance of € 570 – 610 m and adjusted Group EBITDA guidance of € (70) – (105) m.
  • Implementation of Project Horizon, including structural measures expected to generate ~ € 75 m run-rate savings by end of 2027.

Balance sheet and cash flow

  • Net cash provided by (used in) operating activities was € (111,102)k.
  • Net cash provided by (used in) investing activities was € 7,082k, including € 90,557k of proceeds from the disposal of associated companies, other non-current investments and convertibles, net of transaction costs.
  • Evotec received net cash proceeds of € 89,339k from the sale of Tubulis GmbH.
  • Cash and cash equivalents were € 348,356k as of June 30, 2026.
  • Total Liquidity decreased to € 465.6 m.
  • Current and Non-current financial liabilities increased by € 27.1 m to € 475.9 m.
  • Total stockholders' equity decreased by € 148.1 m to € 665.6 m.

Analysis

Evotec reported a materially weaker first half. Group revenue decreased by 19.2% to € 300.1 m, while revenue at constant exchange rates declined by 15.6% to € 313.2 m. Base revenues decreased by 17.8% to € 285.8 m. Management attributed the D&PD decline to weak sales conversion and softer-than-expected customer demand amid a challenging market environment, while JEB's decline was primarily driven by the non-recurring Sandoz License sale in Q1 2025.

The revenue shortfall had a pronounced effect on profitability and utilization. Group gross margin fell to (1.0)% from 13.6%, with D&PD gross margin declining to 4.4% from 15.3% and JEB gross margin declining to (18.3)% from 9.1%. D&PD underutilization persisted, while JEB faced delayed program activities and temporarily higher material and project costs due to production phasing. Adjusted Group EBITDA moved to a loss of € (42.7) m from a loss of € (1.9) m, despite lower cost of revenue and reductions in R&D and SG&A expenses.

Reported losses also incorporated substantial transformation and asset charges. Reorganization costs were € 98.9 m in connection with Project Horizon, and other operating expenses included a € 42.3 m impairment loss related to a Hamburg laboratory building. Net loss totaled € 168.6 m versus a loss of € 75.1 m. The gain from the Tubulis GmbH sale supported non-operating income, with realized gain on investments and financial instruments revaluation of € 70.0 m, but did not offset the operating loss and restructuring charges.

Cash flow weakened alongside operating performance. Net cash used in operating activities was € (111.1) m versus € (5.3) m in 6M 2025. Tubulis proceeds contributed to net cash provided by investing activities of € 7.1 m, and convertible-bond and other-loan proceeds supported financing cash flow of € 33.8 m. Total Liquidity decreased to € 465.6 m, while current and non-current financial liabilities increased to € 475.9 m and the equity ratio declined to 42.3%.

The company updated FY 2026 guidance on July 13, 2026, citing partnership timing shifts and lower revenue conversion. Group revenue is expected at € 570 – 610 m, with adjusted Group EBITDA expected at € (70) – (105) m. Horizon remains central to the recovery plan, with structural measures expected to generate ~ € 75 m run-rate savings by end of 2027. The key operational markers are conversion of D&PD commercial activity into revenue, utilization improvement, and normalization of JEB program timing and cost absorption.

Not in the filing

stated, not guessed
  • GAAP and non-GAAP tax rate
  • Free cash flow
  • Non-GAAP EPS
  • Dividend amount
  • Share repurchase amount
  • Quarterly revenue, margin, earnings, EPS, cash flow, and segment comparisons
  • FY 2026 gross margin guidance
  • FY 2026 operating expenses guidance
  • FY 2026 tax rate guidance

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about EVO earnings dates

When is Evotec's next earnings date?
AlphAI has no date for EVO yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.